Novo Nordisk's Wegovy Gains US Approval for MASH Treatment
TL;DR Summary
Novo Nordisk's weight-loss drug Wegovy has received FDA approval to treat MASH, a serious liver disease affecting about 6% of US adults, giving the company a first-mover advantage in this expanding market for GLP-1 drugs. The drug has shown promise in improving liver fibrosis and reducing inflammation, potentially reversing liver damage in affected patients.
- Novo Nordisk’s Wegovy Gets US Approval for Liver Disease Bloomberg.com
- Novo Nordisk’s obesity drug Wegovy cleared to treat MASH statnews.com
- Wegovy® approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis PR Newswire
- Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH Yahoo Finance
- Novo Nordisk's Wegovy gets accelerated US approval for liver disease MASH Reuters
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
1 min
vs 2 min read
Condensed
82%
304 → 54 words
Want the full story? Read the original article
Read on Bloomberg.com